Vanguard Group Inc An2 Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $5.46 Trillion
- Q3 2024
A detailed history of Vanguard Group Inc transactions in An2 Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,041,527 shares of ANTX stock, worth $1.11 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,041,527
Previous 1,041,527
-0.0%
Holding current value
$1.11 Million
Previous $2.24 Million
50.25%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding ANTX
# of Institutions
33Shares Held
13.5MCall Options Held
0Put Options Held
0-
Bml Capital Management, LLC Zionsville, IN5.75MShares$6.15 Million3.62% of portfolio
-
Ra Capital Management, L.P. Boston, MA2MShares$2.14 Million0.03% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA1.56MShares$1.66 Million0.22% of portfolio
-
Acuitas Investments, LLC446KShares$476,9870.23% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny424KShares$453,4660.0% of portfolio
About AN2 Therapeutics, Inc.
- Ticker ANTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 19,402,700
- Market Cap $20.8M
- Description
- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...